Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

81.18 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,961
Open 81.18
Bid (Size) 82.04 (8)
Ask (Size) 82.11 (4)
Prev. Close 81.18
Today's Range 81.18 - 81.18
52wk Range 80.05 - 148.15
Shares Outstanding N/A
Dividend Yield 1.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Not A Turnaround But Could Be Soon Novo Nordisk
On the weekly chart, NVO fell right down to the 200-week moving average. Clearly the leadership is showing a gross lack of leadership. 
Via Talk Markets
Topics Stocks / Equities
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
A cooler-than-expected December producer inflation report failed to ignite lasting gains on Wall Street Tuesday, reflecting lingering concerns about persistently high inflation among investors. 
Via Benzinga
Topics Economy
Exposures Interest Rates

Performance

YTD
-7.24%
-7.24%
1 Month
-24.87%
-24.87%
3 Month
-31.09%
-31.09%
6 Month
-42.37%
-42.37%
1 Year
-23.67%
-23.67%

More News

Read More
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
Via The Motley Fool
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
Is Novo Nordisk an Undervalued Stock to Buy Now?
Via The Motley Fool
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Via Benzinga
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower
Via Benzinga
What's Going on With Novo Nordisk Stock?
Via The Motley Fool
Better Buy: Novo Nordisk vs. AstraZeneca
Via The Motley Fool
Here's How Much $1000 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
Via Benzinga
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Via Benzinga
Investors Look Back at 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Via Benzinga
President-Elect Trump Poses Challenge To U.S. Tech Sales
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Via Benzinga
Exposures Product Safety
3 Trends To Watch
Via Talk Markets
Topics Stocks / Equities
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Via Benzinga
4 Top Stocks to Buy in January
Via The Motley Fool
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Via Benzinga
Should You Buy the Dip in Novo Nordisk Stock Right Now?
Via The Motley Fool
Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Via MarketBeat
Topics Economy Energy
Exposures Economy Fossil Fuels Interest Rates
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.